RDYDr. Reddy's Laboratories Limited

$13.19-7.2% 1Y

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+1.3 points), but earnings down −24% year on year.

1 good, 1 to watch, 1 neutral
Revenue trend+3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.

Earnings trend−24% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+1.3 points operating

Trailing-twelve-month operating margin, 15.0% now against 13.7% a year earlier.

All from SEC EDGAR, as of Mar 31, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RDY growing?

Dr. Reddy's Laboratories Limited's revenue has grown 11% a year over three years, and grown 12% a year over five, with earnings per share falling 1.7% a year.

+11%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · steady growth, ahead of inflation · compounded from fiscal years as filed

Revenue growth, 5-year rate
+12%

Revenue growth, 5-year rate · +11% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
−1.7%

Earnings per share, 3-year rate · revenue +11% · earnings lagged revenue: the growth is costing something

Years of annual history on file
11

Years of annual history on file · FY2016 to FY2026, as filed

Details›
Revenue FY2022
$214.4B
Revenue FY2023
$245.9B
Revenue FY2024
$279.2B
Revenue FY2025
$325.5B
Revenue FY2026
$335.9B

Annual income statements as filed with the SEC.